Search
Lilly's Olomorasib Granted Breakthrough Therapy Designation by FDA
5 day ago /
Read about 0 minute
Author：小编
Lilly has announced that its drug, Olomorasib, has been awarded Breakthrough Therapy Designation by the Food and Drug Administration (FDA) in the United States. This prestigious designation is specifically for the treatment of newly diagnosed metastatic lung cancer with KRAS G12C mutation. This significant milestone will expedite the development and approval process of the drug, offering a novel therapeutic option and renewed hope to patients affected by this condition.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
